FDA Grants Priority Review to Supplemental Biologics License Application (sBLA) for Merck ’s KEYTRUDA® (pembrolizumab) in Relapsed or Refractory Classical Hodgkin Lymphoma
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
accepted for review the supplemental Biologics License Application
(sBLA) for KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1
therapy, for the treatment of patients with refractory classical Hodgkin
lymphoma (cHL) or for patients who have relapsed after three or more
prior lines of therapy.Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda MSD Source Type: news
More News: Cancer & Oncology | Food and Drug Administration (FDA) | Grants | Lymphoma | Merck | Pharmaceuticals